- Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy
- With a single
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of care
Systemic immune activation was observed in peripheral
The European Commission has approved Agios Pharmaceuticals Inc’s (NASDAQ:AGIO) Pyrukynd (mitapivat) for PK deficiency in adult patients. Pyrukynd is a first-in-class,…
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the ongoing
AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
China trims Covid quarantine time by two days (cnbc.com)
China reduced the quarantine time for international travelers by two days, state media said Friday.
Instead of having to stay at a centralized quarantine
Wednesday, Clearside Biomedical Inc (NASDAQ:CLSD) announced positive results from its OASIS Phase 1/2a trial of CLS-AX (axitinib injectable suspension) in neovascular age-related…